| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Fortress Biotech, Inc. | Chief Financial Officer | Common Stock, par value $0.001 | 163,877 | $389,273 | $2.38 | 21 Sep 2021 | Direct |
| TENAX THERAPEUTICS, INC. | Director | Stock Option (right to buy) | 30,000 | $270,000 | $9.00 | 09 Jan 2026 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| TENX | TENAX THERAPEUTICS, INC. | 09 Jan 2026 | 1 | $0 | 4 | Director | 13 Jan 2026, 19:53 |
| TENX | TENAX THERAPEUTICS, INC. | 01 Jul 2025 | 1 | $0 | 4 | Director | 03 Jul 2025, 08:08 |
| TENX | TENAX THERAPEUTICS, INC. | 10 Dec 2024 | 1 | $0 | 4 | Director | 12 Dec 2024, 20:04 |
| TENX | TENAX THERAPEUTICS, INC. | 09 Jun 2022 | 1 | $0 | 4 | Director | 10 Jun 2022, 21:19 |
| TENX | TENAX THERAPEUTICS, INC. | 28 Jan 2022 | 0 | $0 | 3 | Director | 31 Jan 2022, 16:01 |
| FBIO | Fortress Biotech, Inc. | 21 Sep 2021 | 1 | -$88,554 | 4 | Chief Financial Officer | 29 Apr 2022, 16:25 |